Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
BIOCON | PFIZER | BIOCON / PFIZER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.7 | 45.2 | 76.6% | View Chart |
P/BV | x | 4.4 | 7.5 | 58.7% | View Chart |
Dividend Yield | % | 0.2 | 0.5 | 49.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
PFIZER Mar-19 |
BIOCON / PFIZER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 3,840 | 18.4% | |
Low | Rs | 554 | 2,080 | 26.6% | |
Sales per share (Unadj.) | Rs | 91.9 | 455.0 | 20.2% | |
Earnings per share (Unadj.) | Rs | 16.7 | 93.8 | 17.8% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 109.4 | 22.1% | |
Dividends per share (Unadj.) | Rs | 1.00 | 22.50 | 4.4% | |
Dividend yield (eoy) | % | 0.2 | 0.8 | 20.9% | |
Book value per share (Unadj.) | Rs | 101.6 | 658.2 | 15.4% | |
Shares outstanding (eoy) | m | 600.00 | 45.75 | 1,311.5% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 6.5 | 105.5% | |
Avg P/E ratio | x | 37.7 | 31.6 | 119.6% | |
P/CF ratio (eoy) | x | 26.1 | 27.1 | 96.4% | |
Price / Book Value ratio | x | 6.2 | 4.5 | 138.0% | |
Dividend payout | % | 6.0 | 24.0 | 24.9% | |
Avg Mkt Cap | Rs m | 378,330 | 135,420 | 279.4% | |
No. of employees | `000 | 6.1 | 2.6 | 233.0% | |
Total wages/salary | Rs m | 11,653 | 3,238 | 359.8% | |
Avg. sales/employee | Rs Th | 8,994.3 | 7,911.4 | 113.7% | |
Avg. wages/employee | Rs Th | 1,900.7 | 1,230.9 | 154.4% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 1,630.7 | 100.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 20,815 | 264.9% | |
Other income | Rs m | 1,444 | 1,674 | 86.3% | |
Total revenues | Rs m | 56,588 | 22,489 | 251.6% | |
Gross profit | Rs m | 15,883 | 5,712 | 278.1% | |
Depreciation | Rs m | 4,478 | 714 | 627.3% | |
Interest | Rs m | 709 | 73 | 972.6% | |
Profit before tax | Rs m | 12,140 | 6,599 | 184.0% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,123 | 2,309 | 92.0% | |
Profit after tax | Rs m | 10,026 | 4,291 | 233.7% | |
Gross profit margin | % | 28.8 | 27.4 | 105.0% | |
Effective tax rate | % | 17.5 | 35.0 | 50.0% | |
Net profit margin | % | 18.2 | 20.6 | 88.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 27,167 | 177.5% | |
Current liabilities | Rs m | 30,376 | 8,917 | 340.7% | |
Net working cap to sales | % | 32.4 | 87.7 | 36.9% | |
Current ratio | x | 1.6 | 3.0 | 52.1% | |
Inventory Days | Days | 68 | 68 | 100.7% | |
Debtors Days | Days | 86 | 30 | 284.1% | |
Net fixed assets | Rs m | 64,130 | 8,862 | 723.7% | |
Share capital | Rs m | 3,000 | 458 | 655.7% | |
"Free" reserves | Rs m | 57,980 | 29,656 | 195.5% | |
Net worth | Rs m | 60,980 | 30,113 | 202.5% | |
Long term debt | Rs m | 15,766 | 25 | 63,064.0% | |
Total assets | Rs m | 121,924 | 39,400 | 309.5% | |
Interest coverage | x | 18.1 | 91.5 | 19.8% | |
Debt to equity ratio | x | 0.3 | 0 | 31,142.5% | |
Sales to assets ratio | x | 0.5 | 0.5 | 85.6% | |
Return on assets | % | 8.8 | 11.1 | 79.5% | |
Return on equity | % | 16.4 | 14.2 | 115.4% | |
Return on capital | % | 16.8 | 22.1 | 75.7% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 428 | 3,620.4% | |
Fx outflow | Rs m | 10,399 | 786 | 1,322.4% | |
Net fx | Rs m | 5,107 | -358 | -1,426.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 978 | 1,180.5% | |
From Investments | Rs m | -7,138 | 351 | -2,032.5% | |
From Financial Activity | Rs m | -2,417 | -1,099 | 220.0% | |
Net Cashflow | Rs m | 2,103 | 231 | 911.2% |
Indian Promoters | % | 40.4 | 0.0 | - | |
Foreign collaborators | % | 20.6 | 63.9 | 32.2% | |
Indian inst/Mut Fund | % | 8.4 | 7.5 | 112.0% | |
FIIs | % | 10.7 | 4.9 | 218.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 23.7 | 84.0% | |
Shareholders | 109,995 | 85,207 | 129.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: NATCO PHARMA PANACEA BIOTECH FDC ABBOTT INDIA FRESENIUS KABI ONCO.
Compare BIOCON With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 337 points, up 0.7% at 50,129 levels.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More